The FDA has approved Novavax's Nuvaxovid, a non-mRNA COVID vaccine aimed at adults 65 and high-risk individuals aged 12-64. Although the approval is limited, many people qualify due to underlying conditions. Nuvaxovid offers an effective alternative, with simpler storage and fewer side effects compared to other vaccines. The post The Novavax COVID Vaccine Has Been Approved appeared first on VAXOPEDIA.
